Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash Extracts Biomaterials Growth To Curb Reliance On Angio-Seal

This article was originally published in The Gray Sheet

Executive Summary

Kensey Nash likely will pursue an acquisition strategy and an expanded client base to leverage its biomaterial patents and manufacturing capability
Advertisement

Related Content

Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Distal protection device submission
Distal protection device submission
Orthovita To Double Sales Force For Vitoss Foam, Endoskeleton TA
St. Jude's $167 Mil. Angio-Seal Puncture Closure Buy Adds $50 Mil. In Sales
St. Jude's $167 Mil. Angio-Seal Puncture Closure Buy Adds $50 Mil. In Sales
Advertisement
UsernamePublicRestriction

Register

MT019648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel